CSIMarket Company Name, Ticker, Customers, else..
 
Aclarion Inc   (NASDAQ: ACON)
    Sector • Healthcare    Industry • Medical Laboratories
   Industry • Medical Laboratories
   Sector • Healthcare
 
Price: $2.3500 $0.06 2.620%
Day's High: $2.4100000858306885 Week Perf: 0.00
Day's Low: $ 2.26 30 Day Perf: 0.00
Volume (M): 43,513 52 Wk High: $ 12.03
Volume (M$): $ 0 52 Wk Avg: $4.41
Open: $2.26 52 Wk Low: $1.95



 Market Capitalization (Millions $) 5
 Shares Outstanding (Millions) 2
 Employees 11
 Revenues (TTM) (Millions $) 0
 Net Income (TTM) (Millions $) -8
 Cash Flow (TTM) (Millions $) 4
 Capital Exp. (TTM) (Millions $) 0

Business Description


Aclarion Inc is a technology consulting company that offers a wide range of services related to software development and IT consulting. They specialize in helping businesses leverage technology to improve their efficiency, productivity, and overall performance. Aclarion Inc works with clients from various industries and provides customized solutions to meet their specific needs. Their team of experienced professionals offers expertise in areas such as mobile app development, web development, cloud computing, data analysis, and cybersecurity. Aclarion Inc aims to deliver innovative and reliable solutions that help businesses stay competitive in the ever-evolving digital landscape.


   Company Address: 8181 Arista Place Broomfield 80021 CO
   Company Phone Number: 275-2266   Stock Exchange / Ticker: NASDAQ ACON


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
AMS   -2.72%    
BFLY   -12.69%    
GEHC   -3.99%    
• View Complete Report
   



Product Service News

Aclarions Nociscan Featured by Siemens as a Promising Solution for Chronic Low Back Pain Amid Revenue Fluctuations

Published Thu, Nov 21 2024 1:00 PM UTC

In a notable development within the healthcare technology sector, Aclarion Inc. announced that its pioneering product, Nociscan, has been highlighted in the RSNA (Radiological Society of North America) edition of Siemens’ MAGNETOM Flash. This recognition underscores the growing interest among leading physicians who are increasingly incorporating Nociscan into their clinica...
Product Service News

The Role of Aclarions Nociscan AI in the Comprehensive Comprehension of Modic Changes Pertaining to Chronic Low Back...

Published Fri, Sep 27 2024 10:57 AM UTC

In the annals of contemporary medical enquiry, the understanding of Modic Changes (MC), as discerned through magnetic resonance imaging (MRI), has ascended to prominence, particularly as it is intricately linked to endplate damage, neoinnervation, and the ever-detrimental chronic low back pain (cLBP). In this flourishing epoch of technological advancement, Aclarion, a vangua...
Product Service News

Aclarion Inc.s Nociscan Advancement A Beacon Amidst Market Trials

Published Tue, Sep 10 2024 10:57 AM UTC

In the realm of contemporary medical innovation, Aclarion Inc. has recently unfolded a pivotal chapter within its ambitious LIFEHAB trial. The company has taken significant strides by successfully conducting its inaugural Nociscan examinations, aimed at elucidating the intricate relationship between biomarkers located within the disks of the lumbar spine and the correspondin...
Product Service News

The Dawning of a New Era in Healthcare Aclarion Inc. and the Nociscan Initiative for Personal Injury and Workers Com...

Published Thu, Sep 5 2024 10:57 AM UTC

In the grand theatre of medical progress, where the eldritch shadows of affliction linger, a beacon of hope emerges with the advent of Aclarion Inc.’s strategic partnership with esteemed practitioner, Dr. Justin Kubeck, M.D. of Ocean Pain and Spine, Toms River, New Jersey. This collaboration heralds the introduction of Nociscan, an artificial intelligence technology poised...
Product Service News

Transforming Surgery Aclarions CLUE Trial to Evaluate Nociscans Impact and Address Revenue Trends,

Published Wed, Aug 21 2024 11:57 AM UTC

In a significant advancement within the field of surgical medicine, Aclarion Inc. has officially launched the Clinical Utility and Economic (CLUE) Trial. This innovative study aims to assess how frequently AI-generated biomarker data from Nociscan influences surgical treatment plans formulated by surgeons. The trial will focus on the clinical relevance of Nociscan’s unique...



Fundamental Analysis

Valuation Current
Price to Earnings PE Ratio (TTM) -
Price to Earnings PE Ratio (Expected) -
Price to Sales (TTM) 64.27
Price to Sales (Expected) -
Price to Book 0.25
PEG (TTM) -

Financial Strength Current
Quick Ratio 19.27
Working Capital Ratio 19.65
Leverage Ratio (MRQ) 0.05
Total Debt to Equity -
Interest Coverage (TTM) -
Debt Coverage (TTM) -

Per Share Current
Earnings (TTM) -10.57 $
Revenues (TTM) 0.04 $
Cash Flow (TTM) 2 $
Cash 8.92 $
Book Value 9.23 $
Dividend (TTM) 0 $

Efficiency Current
Revenue per Employee (TTM) 7,080
Net Income per Employee (TTM) -731,797
Receivable Turnover Ratio (TTM) 2.53
Inventory Turnover Ratio (TTM) -
Asset Turnover Ratio (TTM) 0.01

Profitability Ratios Current
Gross Margin (MRQ) 17.74 %
Operating Margin (MRQ) -14129.33 %
Net Margin (MRQ) -13498.46 %
Net Cash Flow Margin (MRQ) 33061.43 %
Effective Tax Rate (TTM) -

Management Effectiveness Current
Return On Assets (TTM) -
Return On Investment (TTM) -
Return On Equity (TTM) -
Dividend Yield -
Pay out Ratio (TTM) -



Aclarion Inc's Segments





Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.